Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
about
Comparison of the safety and pharmacokinetics of ST-246® after i.v. infusion or oral administration in mice, rabbits and monkeysProject BioShield and the Biomedical Advanced Research Development Authority: A ten year progress report on meeting U.S. preparedness objectives for threat agents.Modeling the Effect of Herd Immunity and Contagiousness in Mitigating a Smallpox Outbreak.Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus.Antibody inhibition of a viral type 1 interferon decoy receptor cures a viral disease by restoring interferon signaling in the liver.Experimental infection of cynomolgus macaques (Macaca fascicularis) with aerosolized monkeypox virus.The genome sequence of ectromelia virus Naval and Cornell isolates from outbreaks in North America.A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.Use of the Aerosol Rabbitpox Virus Model for Evaluation of Anti-Poxvirus Agents.Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases.Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies.Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infection.Comparative analysis of monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial inoculation route.A novel respiratory model of infection with monkeypox virus in cynomolgus macaques.Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges.Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.Cowpox virus infection of cynomolgus macaques as a model of hemorrhagic smallpox.Development of ST-246® for Treatment of Poxvirus Infections.Utilizing diversity-oriented synthesis in antimicrobial drug discovery.Small particle aerosol inoculation of cowpox Brighton Red in rhesus monkeys results in a severe respiratory disease.Sequence of pathogenic events in cynomolgus macaques infected with aerosolized monkeypox virus.Susceptibility of Marmosets (Callithrix jacchus) to Monkeypox Virus: A Low Dose Prospective Model for Monkeypox and Smallpox Disease.In vitro inhibition of monkeypox virus production and spread by Interferon-β.Intrabronchial inoculation of cynomolgus macaques with cowpox virusRemaining questions about clinical variola major.Update on new antivirals under development for the treatment of double-stranded DNA virus infectionsInhalational monkeypox virus infection in cynomolgus macaques.Comparative pathology of smallpox and monkeypox in man and macaques.Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine.Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans.Effects of postchallenge administration of ST-246 on dissemination of IHD-J-Luc vaccinia virus in normal mice and in immune-deficient mice reconstituted with T cellsAssessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques.Retrograde Transport from Early Endosomes to the trans-Golgi Network Enables Membrane Wrapping and Egress of Vaccinia Virus Virions.Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox).ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestationOrthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.Animal models of orthopoxvirus infection.A review of experimental and natural infections of animals with monkeypox virus between 1958 and 2012.Historical perspectives in the development of antiviral agents against poxviruses
P2860
Q28741437-63CA25E1-5E85-4CBE-85B4-BA978D9D0924Q30151387-EB27A11F-86F7-48AC-B23B-4CDFEB71DD88Q30205740-AECB664D-30D6-4FD1-92CE-FF41F0204505Q30226522-19FA3786-A059-4BC6-8FDA-3B26EFABC813Q31045190-4720EBA6-39BA-468C-ABB1-047E534DA28FQ33700318-385A463E-97E7-48A4-A2D8-F55D0C17D9EBQ34070278-51E0269D-CB77-4D6D-A755-200377F60E0DQ34126697-4DB330A2-77F3-4E77-B0FE-C518F8101A93Q34196187-F19C3D1B-FDD7-4606-87FB-4DAC75557473Q34457869-0D25C03F-B03C-40F9-80CB-D50B98B7EA5CQ34469836-99495243-1474-4A10-9852-0E67969D9297Q34502253-22842B1C-A96C-485B-8B7E-6721E2225391Q34700352-F65BD479-5094-4532-A79B-958AF5B03AF5Q34742139-48E417C4-8F9A-460A-BD18-197AF7E2457BQ35076685-B19658A6-494C-49DD-B810-B802B65EA3E8Q35140284-56A25D3B-79D2-4249-BF81-4AB7F7ED828EQ35152092-ED82F589-B2FD-4D06-960A-8D6C0941AF9BQ35189550-CFE6C2AD-69DB-4B4F-9A0D-24F731ACDCF8Q35260385-B488433F-8437-4AA4-8792-9D76DCBE3D9AQ35510383-F4768284-9515-4E20-9C73-68DC26C32573Q35578840-C4C5A636-2F45-41D1-9662-BAE2B826A899Q35640911-ADAF9E7C-53F5-4D7F-BB9E-22A92803B410Q35683735-90C9B588-E1BD-4001-BD90-6AF30C73FDB1Q35772104-5F44C948-16CC-47FD-8F1D-ECABD23E564EQ35960459-58B4619D-3FA5-4870-934C-9990B580E102Q36039631-555699A1-3782-4F2A-A41B-5494CF5BF190Q36185647-45DD3861-1C90-4728-8BBB-1CBEFFAFB50CQ36238053-8404694D-4B0B-4D4A-85BB-554EC457B31AQ36400333-74338304-2056-4472-8135-9D11D49A984EQ36559797-3277163D-A8F9-4308-855A-020F1B500E91Q36667010-7F4F6B21-9582-4A8C-8988-40B0AF9F2998Q36827391-D48375B1-440E-43E7-B298-1708EE1921F8Q36978610-6C7C1533-B2D0-49B4-88F8-DE88ABAB3E81Q37252890-6F4D3B5C-E5CD-4AF0-9F42-EBC8920B6882Q37335688-BCE7ABC5-A368-4298-B016-63904465E3CAQ37450819-46FBECBC-D5AE-46CC-91B5-F3763BA71ABBQ37593480-6230C519-F69E-4D2D-B4EB-E9C19403FA73Q37777545-200FDA9D-684E-4D8A-AB4F-B4AE4D000A62Q38102696-6900E932-3142-42BA-AF88-66AC57180EE4Q38617932-BF9C2825-B87E-4E4D-A3B2-113AEF7E3E37
P2860
Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Nonhuman primates are protecte ...... by the antiviral drug ST-246.
@en
Nonhuman primates are protecte ...... by the antiviral drug ST-246.
@nl
type
label
Nonhuman primates are protecte ...... by the antiviral drug ST-246.
@en
Nonhuman primates are protecte ...... by the antiviral drug ST-246.
@nl
prefLabel
Nonhuman primates are protecte ...... by the antiviral drug ST-246.
@en
Nonhuman primates are protecte ...... by the antiviral drug ST-246.
@nl
P2093
P2860
P356
P1476
Nonhuman primates are protecte ...... by the antiviral drug ST-246.
@en
P2093
Arthur Goff
Carly Wlazlowski
Chelsea M Byrd
Dennis Hruby
Eric Mucker
Inger K Damon
Jennifer Chapman
John Huggins
Josh Shamblin
Kevin Karem
P2860
P304
P356
10.1128/AAC.00021-09
P407
P577
2009-04-06T00:00:00Z